Yunfeng Capital and Gaorong Capital led a USD200m Series B for Sironax, a China-based clinical-stage biotech with a focus on the treatment of age-related degenerative disease, with participation from MSA Capital, a subsidiary of Abu Dhabi Investment Authority (ADIA), CBC Group, Long River Investments, LSV Capital, Superstring Capital and Future Innovation Fund, and follow-on from Temasek, Invus, F-Prime Capital, Eight Roads Capital, ARCH Venture Partners and K2 Venture Partners. Read more